Pfizer Inc. (PFE) To Go Ex-Dividend on July 24th

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, June 24th. Shareholders of record on Friday, July 24th will be paid a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 1st. This represents a c) annualized dividend and a yield of 7.3%. The ex-dividend date is Friday, July 24th.

Pfizer has decreased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a dividend payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Pfizer to earn $2.86 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 60.1%.

Pfizer Trading Down 1.7%

NYSE PFE opened at $23.64 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market cap of $134.71 billion, a PE ratio of 18.04 and a beta of 0.34. Pfizer has a one year low of $23.11 and a one year high of $28.75. The firm’s fifty day moving average is $26.00 and its two-hundred day moving average is $26.30.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer will post 2.99 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA bought a new stake in Pfizer during the 3rd quarter valued at $16,613,000. Mackenzie Financial Corp grew its stake in shares of Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its holdings in shares of Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Pfizer during the third quarter valued at about $81,298,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.